ALFA Filings
Every announcement, straight from the exchange
Every Aurobindo Pharma business update announcement on NSE and BSE, newest first, each with its own page.
Time
9 announcements
Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.
Aurobindo Pharma announced that the US FDA inspection of its subsidiary Apitoria Pharma's Unit-IV concluded with zero observations. This signals continued regulatory compliance for the facility.
Aurobindo Pharma reported the completion of a US FDA inspection at its subsidiary, Lannett Company LLC, which resulted in four procedural observations.
Aurobindo Pharma's subsidiary, Eugia Pharma Specialities Ltd., received a US FDA Warning Letter for its Unit I manufacturing facility. The unit contributes approximately 2% to group revenue.
Aurobindo Pharma has submitted its Business Responsibility & Sustainability Report for the financial year 2025-26 to the stock exchanges.
Aurobindo Pharma signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply generic alimatravir for 129 low- and middle-income countries.
US FDA completed an inspection at Auroactive Pharma, a wholly owned subsidiary. The inspection resulted in two observations to be responded to.
Aurobindo Pharma subsidiary's Unit-I facility received an 'official action indicated' (OAI) classification from the US FDA. The company maintains there is no financial impact.
Aurobindo Pharma's Unit-VII in Telangana received an Establishment Inspection Report (EIR) from the US FDA. The facility is classified as Voluntary Action Indicated (VAI), and the inspection is now closed. This follows a January-February 2026 inspection that initially resulted in nine observations.